141 related articles for article (PubMed ID: 34953891)
1. A novel aryl-guanidinium derivative, VP79s, targets the signal transducer and activator of transcription 3 signaling pathway, downregulates myeloid cell leukaemia-1 and exhibits preclinical activity against multiple myeloma.
Amet R; Previtali V; Mihigo HB; Sheridan E; Brophy S; Hante NK; Santos-Martinez MJ; Hayden PJ; Browne PV; Rozas I; McElligott AM; Zisterer DM
Life Sci; 2022 Feb; 290():120236. PubMed ID: 34953891
[TBL] [Abstract][Full Text] [Related]
2. As
Wu D; Dong W; Fang K; Wang M
Technol Cancer Res Treat; 2019; 18():1533033819896806. PubMed ID: 31868118
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
4. Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.
Burger R; Le Gouill S; Tai YT; Shringarpure R; Tassone P; Neri P; Podar K; Catley L; Hideshima T; Chauhan D; Caulder E; Neilan CL; Vaddi K; Li J; Gramatzki M; Fridman JS; Anderson KC
Mol Cancer Ther; 2009 Jan; 8(1):26-35. PubMed ID: 19139110
[TBL] [Abstract][Full Text] [Related]
5. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
Li J; Favata M; Kelley JA; Caulder E; Thomas B; Wen X; Sparks RB; Arvanitis A; Rogers JD; Combs AP; Vaddi K; Solomon KA; Scherle PA; Newton R; Fridman JS
Neoplasia; 2010 Jan; 12(1):28-38. PubMed ID: 20072651
[TBL] [Abstract][Full Text] [Related]
6. Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor.
Muto A; Hori M; Sasaki Y; Saitoh A; Yasuda I; Maekawa T; Uchida T; Asakura K; Nakazato T; Kaneda T; Kizaki M; Ikeda Y; Yoshida T
Mol Cancer Ther; 2007 Mar; 6(3):987-94. PubMed ID: 17363492
[TBL] [Abstract][Full Text] [Related]
7. Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway.
Li F; Rajendran P; Sethi G
Br J Pharmacol; 2010 Oct; 161(3):541-54. PubMed ID: 20880395
[TBL] [Abstract][Full Text] [Related]
8. Death of multiple myeloma cells induced by cAMP-signaling involves downregulation of Mcl-1 via the JAK/STAT pathway.
Follin-Arbelet V; Torgersen ML; Naderi EH; Misund K; Sundan A; Blomhoff HK
Cancer Lett; 2013 Jul; 335(2):323-31. PubMed ID: 23454584
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.
Gupta VA; Matulis SM; Conage-Pough JE; Nooka AK; Kaufman JL; Lonial S; Boise LH
Blood; 2017 Apr; 129(14):1969-1979. PubMed ID: 28151428
[TBL] [Abstract][Full Text] [Related]
10. Genipin induces mitochondrial dysfunction and apoptosis via downregulation of Stat3/mcl-1 pathway in gastric cancer.
Jo MJ; Jeong S; Yun HK; Kim DY; Kim BR; Kim JL; Na YJ; Park SH; Jeong YA; Kim BG; Ashktorab H; Smoot DT; Heo JY; Han J; Lee DH; Oh SC
BMC Cancer; 2019 Jul; 19(1):739. PubMed ID: 31351462
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of JAK1/STAT3 signaling mediates compound K-induced apoptosis in human multiple myeloma U266 cells.
Park S; Lee HJ; Jeong SJ; Song HS; Kim M; Lee HJ; Lee EO; Kim DH; Ahn KS; Kim SH
Food Chem Toxicol; 2011 Jun; 49(6):1367-72. PubMed ID: 21420464
[TBL] [Abstract][Full Text] [Related]
12. Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.
Wagner V; Hose D; Seckinger A; Weiz L; Meißner T; Rème T; Breitkreutz I; Podar K; Ho AD; Goldschmidt H; Krämer A; Klein B; Raab MS
Oncotarget; 2014 Nov; 5(21):10237-50. PubMed ID: 25296978
[TBL] [Abstract][Full Text] [Related]
13. Matrine suppresses cell growth of human chronic myeloid leukemia cells via its inhibition of the interleukin-6/Janus activated kinase/signal transducer and activator of transcription 3 signaling cohort.
Ma L; Zhu Z; Jiang L; Sun X; Lu X; Zhou M; Qian S; Jianyong L
Leuk Lymphoma; 2015; 56(10):2923-30. PubMed ID: 25629992
[TBL] [Abstract][Full Text] [Related]
14. A novel requirement for Janus kinases as mediators of drug resistance induced by fibroblast growth factor-2 in human cancer cells.
Carmo CR; Lyons-Lewis J; Seckl MJ; Costa-Pereira AP
PLoS One; 2011; 6(5):e19861. PubMed ID: 21625473
[TBL] [Abstract][Full Text] [Related]
15. Blockage of the JAK/STAT3 signaling pathway in multiple myeloma by leelamine.
Jung YY; Um JY; Nasif O; Alharbi SA; Sethi G; Ahn KS
Phytomedicine; 2021 Jul; 87():153574. PubMed ID: 34006448
[TBL] [Abstract][Full Text] [Related]
16. A sesquiterpene lactone antrocin from Antrodia camphorata negatively modulates JAK2/STAT3 signaling via microRNA let-7c and induces apoptosis in lung cancer cells.
Yeh CT; Huang WC; Rao YK; Ye M; Lee WH; Wang LS; Tzeng DT; Wu CH; Shieh YS; Huang CY; Chen YJ; Hsiao M; Wu AT; Yang Z; Tzeng YM
Carcinogenesis; 2013 Dec; 34(12):2918-28. PubMed ID: 23880305
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation.
Brocke-Heidrich K; Kretzschmar AK; Pfeifer G; Henze C; Löffler D; Koczan D; Thiesen HJ; Burger R; Gramatzki M; Horn F
Blood; 2004 Jan; 103(1):242-51. PubMed ID: 12969979
[TBL] [Abstract][Full Text] [Related]
18. [IL-6 Regulates the Chemosensitivity of Drug-Resistant Multiple Myeloma Cell Lines to Bortezomib through STAT3/Notch Signaling Pathway].
Liu Y; Sui JZ; Zhu LH; Dai Y; Dong HQ; Cheng P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1474-1481. PubMed ID: 36208252
[TBL] [Abstract][Full Text] [Related]
19. Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells.
Kim SH; Ahn KS; Jeong SJ; Kwon TR; Jung JH; Yun SM; Han I; Lee SG; Kim DK; Kang M; Chen CY; Lee JW; Kim SH
Eur J Pharmacol; 2011 Mar; 654(1):10-6. PubMed ID: 21172343
[TBL] [Abstract][Full Text] [Related]
20. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
Monaghan KA; Khong T; Burns CJ; Spencer A
Leukemia; 2011 Dec; 25(12):1891-9. PubMed ID: 21788946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
